Methoxygonadiene (Max LMG)
Methoxygonadiene ('Max LMG', 13-ethyl-3-methoxy-gona-2,5(10)-dien-17-one) is an orally active 19-nor designer prohormone that acts largely as a progestin/prohormone toward dienolone-type 19-nor androgens. Sold to add 'wet' size and enhance stacked compounds, it is progestogenic, non-aromatising, and — being non-methylated at C17 — comparatively less hepatotoxic than typical designer orals, though still suppressive.
01 Overview
Methoxygonadiene is a gona-diene ether prohormone related to the norgestrel family. Rather than being a strong direct androgen, it behaves as a progestin and a weak precursor, and is usually run as a base or 'stacker' with more androgenic orals to add fullness and mass.
Unlike most designer orals it lacks 17-alpha-alkylation, so hepatic strain is lower; however its progestogenic activity drives suppression and progestin-type side effects. Human data are essentially absent.
02 Mechanism
Enol-ether prohormone with progestin activity that can convert toward dienolone-type 19-nor androgens; acts on androgen and progesterone receptors. Not 17-alpha-alkylated.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 25–75 mg/day | Oral | Often run as a base compound in stacks. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased fullness/sizeProgestogenic nutrient partitioning reported to add fullness. | modest, 'wet' | Anecdotal | |
| Synergy in stacksPopular as a low-liver-strain base with androgenic orals. | unclear | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Progestin side effectsLethargy, libido loss and possible nipple sensitivity. | Moderate | Common | Anecdotal | |
| HPTA suppressionStrong suppression despite being non-methylated. | Severe | Universal | Anecdotal |